Wembacher-Schroeder Eva, Kerstein Nicole, Bander Evan D, Pandit-Taskar Neeta, Thomson Rowena, Souweidane Mark M
1Brainlab AG, Munich, Germany.
2Department of Neurological Surgery, Weill Medical College of Cornell University, New York, New York.
J Neurosurg Pediatr. 2021 May 14;28(1):34-42. doi: 10.3171/2020.11.PEDS20571. Print 2021 Jul 1.
With increasing use of convection-enhanced delivery (CED) of drugs, the need for software that can predict infusion distribution has grown. In the context of a phase I clinical trial for pediatric diffuse intrinsic pontine glioma (DIPG), CED was used to administer an anti-B7H3 radiolabeled monoclonal antibody, iodine-124-labeled omburtamab. In this study, the authors retrospectively evaluated a software algorithm (iPlan Flow) for the estimation of infusate distribution based on the planned catheter trajectory, infusion parameters, and patient-specific MRI. The actual infusate distribution, as determined on MRI and PET imaging, was compared to the distribution estimated by the software algorithm. Similarity metrics were used to quantify the agreement between predicted and actual distributions.
Ten pediatric patients treated at the same dose level in the NCT01502917 trial conducted at Memorial Sloan Kettering Cancer Center were considered for this retrospective analysis. T2-weighted MRI in combination with PET imaging was used to determine the distribution of infusate in this study. The software algorithm was applied for the generation of estimated fluid distribution maps. Similarity measures included object volumes, intersection volume, union volume, Dice coefficient, volume difference, and the center and average surface distances. Acceptable similarity was defined as a simulated distribution volume (Vd Sim) object that had a Dice coefficient higher than or equal to 0.7, a false-negative rate (FNR) lower than 50%, and a positive predictive value (PPV) higher than 50% compared to the actual Vd (Vd PET).
Data for 10 patients with a mean infusion volume of 4.29 ml (range 3.84-4.48 ml) were available for software evaluation. The mean Vd Sim found to be covered by the actual PET distribution (PPV) was 77% ± 8%. The mean percentage of PET volume found to be outside the simulated volume (FNR) was 34% ± 10%. The mean Dice coefficient was 0.7 ± 0.05. In 8 out of 10 patients, the simulation algorithm fulfilled the combined acceptance criteria for similarity.
iPlan Flow software can be useful to support planning of trajectories that produce intraparenchymal convection. The simulation algorithm is able to model the likely infusate distribution for a CED treatment in DIPG patients. The combination of trajectory planning guidelines and infusion simulation in the software can be used prospectively to optimize personalized CED treatment.
随着对流增强药物递送(CED)的使用日益增加,对能够预测输注分布的软件的需求也在增长。在一项针对小儿弥漫性脑桥内在型胶质瘤(DIPG)的I期临床试验中,使用CED来给予一种抗B7H3放射性标记的单克隆抗体,即碘-124标记的omburtamab。在本研究中,作者回顾性评估了一种软件算法(iPlan Flow),该算法可根据计划的导管轨迹、输注参数和患者特异性MRI来估计输注物的分布。将MRI和PET成像确定的实际输注物分布与软件算法估计的分布进行比较。使用相似性指标来量化预测分布与实际分布之间的一致性。
本回顾性分析纳入了在纪念斯隆凯特琳癌症中心进行的NCT01502917试验中接受相同剂量水平治疗的10例儿科患者。本研究中使用T2加权MRI结合PET成像来确定输注物的分布。应用软件算法生成估计的液体分布图。相似性测量包括物体体积、交集体积、并集体积、骰子系数、体积差异以及中心和平均表面距离。可接受的相似性定义为模拟分布体积(Vd Sim)物体,与实际Vd(Vd PET)相比,其骰子系数高于或等于0.7,假阴性率(FNR)低于50%,阳性预测值(PPV)高于50%。
有10例患者的数据可用于软件评估,平均输注体积为4.29 ml(范围3.84 - 4.48 ml)。发现实际PET分布所覆盖的平均Vd Sim(PPV)为77%±8%。发现PET体积超出模拟体积的平均百分比(FNR)为34%±10%。平均骰子系数为0.7±0.05。10例患者中有8例的模拟算法符合相似性的综合接受标准。
iPlan Flow软件有助于支持产生脑实质内对流的轨迹规划。该模拟算法能够模拟DIPG患者CED治疗中可能的输注物分布。软件中的轨迹规划指南与输注模拟相结合可前瞻性地用于优化个性化CED治疗。